When an immunocompromised person's system starts to heal and create more white blood cells, it's usually a healthy sign - unless they acquire a potentially fatal inflammatory condition.
According to new research from the University of Illinois Urbana-Champaign, the pulmonary distress commonly associated with the illness is generated not by lung injury, but by freshly populated T-cells entering the brain.
Knowing this mode of action can help researchers and doctors better understand the illness and identify new therapeutic targets, according to study leader Makoto Inoue, an Illinois professor of comparative biosciences. The findings were reported in the journal Nature Communications.
Cryptococcus-associated immune reconstitution inflammatory syndrome, known as C-IRIS, happens when an immunocompromised patient is unknowingly infected with the fungus Cryptococcus. Once the patient’s immune system begins to rebuild, creating more T-cells, the infection sparks systemic inflammation.
C-IRIS frequently affects patients receiving antiretroviral therapy, recovering from chemotherapy, or recovering from a transplant, and also has been known to affect postpartum women or patients with multiple sclerosis – yet it remains difficult to diagnose, requiring ruling out other causes first, said study co-author Jinyan Zhou, a graduate student researcher at Illinois.
Wanting to understand more about the condition and its progression, the researchers developed a mouse model of the disease. To achieve this, they give injections of T-cells to immune-deficient mice preinfected with Cryptococcus, simulating what happens when the immune system starts producing higher levels of T-cells after being suppressed. The symptoms the mice developed – such as inflammation, fluid in the brain and pulmonary dysfunction – were in line with those of human patients.
“We saw a high number of T-cells infiltrating the brains in conjunction with the presence of pulmonary dysfunctions, so that told us they could be connected,” Zhou said.
“In healthy conditions, there shouldn’t be that many T-cells in the brain, because those cells should primarily exist in the periphery with a small number of T-cells doing patrol and surveillance within the brain.”
When the researchers investigated further, they uncovered a chain of events leading the T-cells to invade the brain and affect breathing. The receptor CCR5 is implicated in HIV and cancer and also found on the surface of T-cells.
When the T-cell populations started to rise in the mice, the receptor promoted the white blood cells’ infiltration into the brain. In addition, the T-cells that had infiltrated the brain produced high amounts of two molecules known to cause damage to neurons in the regions of the brain that control respiratory function.
“Finding that the pulmonary dysfunction is due to neuron damage in the brain was a new way of seeing this condition,” Inoue said. “We know the brain controls many peripheral organs, but this is a notable idea for clinicians treating this syndrome. Normally, drugs are given to try to improve lung function, but they don’t work. Now we know it’s due to changes in the brain, so that gives us new treatment pathways to target.”
To verify this chain of events and identify potential treatment pathways, the researchers treated a set of mice with a drug that suppresses the CCR5 receptor. Both pulmonary function and neuronal development improved.
“We think this could have the potential to be beneficial for C-IRIS patients as well, to prevent T-cell infiltration into the brain, and that in turn could prevent the symptoms from happening,” Zhou said.
“We also could target those molecules that damage the neurons. For example, when patients are prescribed immunotherapies we could maybe manipulate those T-cells to decrease their expression of those molecules.”
Next, the researchers plan to further study other functions of the immune system in C-IRIS and how more systems in the brain and body interact with T-cells.
READ ALSO:
